New hope for rare skin disease: drug combo targets stubborn pustules on palms and soles
NCT ID NCT07530367
First seen Apr 17, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests whether combining two drugs, tofacitinib and imatinib, can safely treat moderate-to-severe palmoplantar pustulosis (PPP), a rare skin disease causing painful pustules on the palms and soles. About 135 adults will receive either the drug combination or a placebo for 16 weeks. The main goal is to see if the treatment can reduce symptoms by at least 90%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.